#Osteoporosis Drugs Market Share

[mrfrblogresearch02]

Osteoporosis Drugs Market growth to Deliver Greater Revenues during the Forecast Period till 2027

Overview:

The global Osteoporosis Market Growth is currently eyeing for a staggering USD 14,300 million valuation during the forecast period (2013-2022), claims Market Research Future (MRFR) in a detailed study. Booming urbanization and technological advancements may have a lot to do with the progressing world, but they have some adverse effects too. Osteoporosis is one such side-effect of the fast-evolving lifestyle and the inflating osteoporosis drugs market is a direct result of that. The market is about to witness a moderate CAGR of 4.7% during the forecast period.

Drivers and Restraints:

Osteoporosis follows a genetic map in targeting people. The Caucasians are more susceptible to osteoporosis, and the Asians come next. Whereas, the Africans are the least in number to suffer from this disease. Along with this gender bias, a rise in geriatric population, alcoholism and smoking, the prevalence of various disease such as cancer, autoimmune disorders, thalassemia, hormonal and disorders are also affecting the bone condition of the mass.

Adoption of a sedentary lifestyle triggered by work-related pressures and technological advancements is also one of the chief driving force for the osteoporosis drug market. Furthermore, women are more prone to this disease. This has given rise to awareness and technological and medical awareness which also giving the market a much-needed thrust.

However, blockbuster drugs losing patents, generic drugs penetrating the market and creating fragments in the market, and side-effects of present therapies can bottleneck the market growth. But patients are now quickly realizing its importance and how it can lead to further damages such as hip fractures which will bring back the wind in the market’s favor.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/2479

Industry News:

Recent research published in the New England Journal of Medicine (NEJM) claims that alendronate increases bone density by curbing the bone fragmentation and reduces the risk factor by 20%-50%. This can be beneficial for the global osteoporosis drug market.

Segmentation:

The global market for osteoporosis drug market can be segmented by drug class, route of administration and gender.

By drug class, the market can be segmented into bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. Bisphosphonates are currently leading the market. The drug is the most commonly prescribed medicine resulting in the medicine capturing almost half of the market.

On the basis of route of administration, the market comprises oral, injectable and others.  

Based on gender, the market comprises male and female. However, women are more prone to this disease. As per the studies of the International Osteoporosis Foundation (IOF), worldwide over a billion women are now suffering from the disease.

Regional Analysis:

The global osteoporosis drug market covers the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

The Americas has the largest market owing to a rising geriatric population and advanced healthcare setup. Also, the reimbursement policies are pretty patient-friendly resulting in the growth of the market. People here are more aware of the consequences, that is why they prefer timely action. Hence, the market is snowballing.

Europe is second in the market and technologically advanced healthcare sector is proving to be a boon for the market. Rising number of population with disposable income and easy reimbursement policies act as a market booster.

The APAC comes next where China and India are expected to play significant role. These two countries have a huge population base, and the market is benefitting much from their very well-structured healthcare sector.

The MEA is expecting the least growth. Healthcare sector is not that developed, and people act ignorant. Reimbursement policies are not that well-formed. These are factors holding the market back.

Market Dashboard:

The market is mainly getting driven by mergers and acquisitions. For instance, Novartis has recently acquired AveXis, Inc. On the other hand, F. Hoffmann La Roche Ltd. reached an agreement with Foundation Medicine regarding a definitive merger.  

Some of the key players in this market are Eli Lilly and Company, Merck & Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd. and others.

Browse Detailed TOC with COVID-19 Impact Analysis at:

https://www.marketresearchfuture.com/reports/osteoporosis-drugs-market-2479

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

[techsciresearch]

Osteoporosis Drugs Market to be Valued USD 20.17 Billion by 2026

Rising prevalence of osteoporosis and surge in geriatric population to drive the global osteoporosis drugs market.

According to TechSci Research report, “Global Osteoporosis Drugs Market By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), By Osteoporosis Disease Type (Primary Osteoporosis, Secondary Osteoporosis), By Route of Administration (Oral, Injectable, and Others), By Gender (Female, Male), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Forecast & Opportunities, 2026”, the market is anticipated to grow at a healthy CAGR during the forecast period. The key factors propelling the growth of the global osteoporosis drugs market include rising prevalence of osteoporosis and surge in geriatric population around the world as they pose high susceptibility for osteoporosis. Growing adoption of sedentary lifestyle is also impacting bone health and thus, there is a rise in demand for osteoporosis drugs. Additionally, the increase in osteoporosis cases due to menopause in women is acting as a major growth driver for this market. In men, lifestyle associated factors such as smoking and alcohol abuse are found to promote osteoporosis. This is further expected to augment the global osteoporosis drugs market through 2026.

Moreover, increasing investment in R&D activities for the development of advanced new drug classes is also fueling the market growth. The wide range of pipeline drugs for approval in clinical trials are also expected to provide lucrative growth opportunities for osteoporosis drug manufacturers. However, the market is also prone to some challenges. Several side effects of osteoporosis drugs such as heartburn, nausea, irritable bowel syndrome and ulcers in the stomach are likely to hamper the market growth. Furthermore, the time-taking drug approval process is also anticipated to restrain the global osteoporosis drugs market growth.

Browse 182 Figures spread through 110 Pages and an in-depth TOC on "Global Osteoporosis Drugs Market"

https://www.techsciresearch.com/report/osteoporosis-drugs-market/5081.html

Global osteoporosis drugs market can be segmented based on disease type, drug class, route of administration, gender, distribution channel and region. Based on drug class, the market can be segmented into bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Among them, parathyroid hormone therapy are expected to register highest CAGR during the forecast period as they are increasingly being used to treat osteoporosis and have lesser side effects.

Based on route of administration, global osteoporosis drugs market can be segmented into oral, injectable, and others. Among them, the oral segment accounted for largest market share in 2020 owing to abundant availability of medications which are taken orally. However, the injectable segment is anticipated to witness fastest growth through 2026 owing to growing need for drugs that exhibit improved bioavailability rapid mode of action.

Major companies operating in global osteoporosis drugs market include F. Hoffmann-La Roche Ltd, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Novartis International AG, GlaxoSmithKline Plc, Merck & Co. Inc., Amgen, Inc., Allergan plc, Eli Lilly and Company, Radius Health, Inc., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited, Sanofi S.A., Abiogen Pharma S.p.A., Merrion Pharmaceuticals Plc., among others. The companies are undergoing new product development and collaborative research initiatives to increase their share in global osteoporosis drugs market.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5081

Customers can also request for 10% free customization on this report.

“North America dominated the global osteoporosis drugs market in 2020 and is expected to hold its dominance through 2026 owing to rising prevalence of osteoporosis and easy availability of osteoporosis drugs in the region. However, Asia Pacific is anticipated to undergo fastest growth during the forecast period due to thriving life science industry and growing awareness about the benefits of osteoporosis drugs,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Osteoporosis Drugs Market By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), By Osteoporosis Disease Type (Primary Osteoporosis, Secondary Osteoporosis), By Route of Administration (Oral, Injectable, and Others), By Gender (Female, Male), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Forecast & Opportunities, 2026” has evaluated the future growth potential of global osteoporosis drugs market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global osteoporosis drugs market.

Our Blog : https://techsciblog.com/

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Web : https://www.techsciresearch.com/

[sapanas]

Osteoporosis Drugs Market 2020: Company Profiles, Business Trends, Industry Segments, Landscape and Demand

Market Report Titled "Osteoporosis Drugs Market Research Report – Forecast to 2022" is a Specialist Examination Report Explores the Market by Research Methodology, Segmentation, Key Players, and Major Region Globally.

Osteoporosis Drugs Market Analysis

Osteoporosis is a disorder that causes a lower bone mass that results in weakening and micro-architectural deterioration of bone tissues.  Osteoporosis makes bones so brittle that a minor injury or even mild stresses like bending over or coughing can cause a fracture. Osteoporosis drugs are useful in the treatment of low bone density, slowing down bone resorption. These medications reduce the likelihood of having fragility fractures.

The global osteoporosis drugs market is well-established, and there are various effective medicines available to treat the disorder which is invariably driving the growth of the market. Moreover, a growing number of drug manufacturers are escalating the market on the global platform, bringing novel medications in the market.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/2479

Recognizing the colossal traction and gauging the potential of the market to grow in forthcoming years; Market Research Future (MRFR), in its newly published study analysis asserts that the global osteoporosis drugs market will reach a valuation of USD 14,300 MN by 2022, growing at7.2% CAGR over the review period (2017 – 2022).

Additional factors helping the market to grow further include the rise in the geriatric population, gene mutations, changing lifestyle, and addictions such as alcoholism and smoking. Also, drug-induced osteoporosis and rising prevalence of diseases and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, and hormonal disorders, are some of the key factors propelling the growth of the market.

Conversely, factors such as the patent expiries of blockbuster medicines, side effects of these drugs, and the availability of generics are impeding the growth of the market. Also, in some cases, osteoporosis shows very low or poor symptoms which obstructs the market growth.

Nevertheless, factors such as substantial technological strides that have made the osteoporosis drugs more effective, increasing the demand for the treatment measures for osteoporosis are expected to fuel the growth of the market.

Besides, substantial investments transpired into R&D activities, and improving economic conditions would provide impetus to the growth of the market, increasing the healthcare expenditures and access to excellent health care.

Global Osteoporosis Drugs Market – Segments

For ease of understanding, the Osteoporosis Drugs Market analysis has been segmented into four key dynamics:  

By Drug Class: Bisphosphonates, Calcitonins, Selective Estrogen Receptor Modulators (SERMs), and Parathyroid Hormone (PTH) among others.

By Route Of Administration: Oral and Injectable among others.

By Gender : Male and Female

By Regions : North America, Asia Pacific, Europe, and the Rest-of-the-World.

Global Osteoporosis Drugs Market – Regional Analysis

The North American region, heading with the increasing prevalence of osteoporosis is estimated to retain its dominance over the global osteoporosis drugs market. Additional factors such as the presence of a well-developed healthcare sector, high per capita healthcare expenditures, and well-spread awareness drives the regional market.

Furthermore, growing markets in the U.S. and Canada backed by the presence of prominent market players impacts the growth of the regional market, positively.  The region is expected to create a significant revenue pocket registering a robust CAGR throughout the forecast period (2017-2022).

The osteoporosis market in the European region accounts for the second-largest market, globally. Factors such as favorable government support and initiatives and the proliferating healthcare sector backed by the resurging economy are radiantly fostering the growth of the market in the region.

The U.K., backed by its sizeable osteoporosis drugs market and Germany with its vast medical technology and pharmaceutical industry, significantly contributes to the growth of the regional market, is expected to drive the market growth in the region.

The Asia Pacific osteoporosis drugs market is rapidly emerging as a promising market, globally. Factors such as the spreading awareness towards the disorder and women healthcare alongside the availability of many novel drugs influence the growth of the market, positively.

Moreover, the rising prevalence of osteoporosis in women after menopause, gene mutations, changing lifestyle, and the burgeoning pharmaceutical industry support the growth of the regional market. Furthermore, continually rising healthcare expenditures and favorable government policies, especially in the developing countries like China and India substantiate the market growth in the APAC region.

Global Osteoporosis Drugs Market – Competitive Analysis

Fiercely competitive, the osteoporosis drugs market appears fragmented with many large and small players churning the competition. Through the strategic initiatives such as partnership, expansion, acquisition, collaboration, and product & technology launch these players try to gain an edge over their competitors.

Osteoporosis Drugs Market Major Players:

Key players leading the global osteoporosis drugs market include Merck & Co., Eli Lilly and Company, Novartis International AG, F. Hoffmann La Roche Ltd., Amgen Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Novo Nordisk among others.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/osteoporosis-drugs-market-2479

Osteoporosis Drugs Industry, Innovation & Related News

April 16, 2019 –--- Two leading global biopharmaceutical companies UCB (Belgium) and Amgen Inc. (the US) announced the receiving of the US FDA approval for the osteoporosis drug – Evenity that they have developed, collaboratively. This drug is approved to treat osteoporosis in postmenopausal women at high risk of bone fracture. Evenity represents the first new treatment approach after nearly two decades, restoring bone without breaking it down. Based on a rare gene mutation in people with bones so dense that they never break, Evenity, can increase bone formation and decrease bone loss.

[kajal-jadhaw-me]

The detailed examination of recent developments including collaboration, mergers and acquisitions, investment and product launches have also been performed during the research on the Osteoporosis Drugs Market. Overview of the gradual shift in the customer preference, spending power, consumption volume and production capability helps business owners understand where the market will be heading in the years to come. Vital statistics on distribution channel and supply chain management across different regions are presented through different resources such as tables, charts and graphic images. Read more: http://www.digitaljournal.com/pr/4253267#ixzz6LZgVjY7R

[monaligvr-blog]

Osteoporosis Drugs Market  Growth Factors, Trends and Forecast Report to 2025

San Francisco, 16 January 2019 –  “Osteoporosis Drugs Market Analysis By Product (Branded, Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), Rank Ligand Inhibitors, Generics), And Segment Forecasts, [2018 - 2025]”

The global osteoporosis drugs market is expected to reach USD 16.3 billion by 2025, according to a new study by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Browse Research Report On Osteoporosis Drugs Market : www.grandviewresearch.com/industry-analysis/osteoporosis-drug-market

Further key findings from the study suggest:

Branded drugs held the dominant share of the product segment in 2015. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy

Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies

In 2015, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics

Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care

The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

View more reports of this category by Grand View Research at www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the osteoporosis drugs market on the basis of product and region:

Global Osteoporosis Product Outlook (Revenue, USD Million, 2014 – 2025)

Branded

Bisphosphonates

Parathyroid Hormone Therapy

Calcitonin

Selective Estrogen Inhibitors Modulator(SERM)

Rank Ligand Inhibitors

Others

Generics

Osteoporosis Drugs Regional Outlook (Revenue, USD Billion, 2014 – 2025)

North America

U.S.

Canada

Europe

UK

Germany

Asia Pacific

Japan

China

India

Latin America

Mexico

Brazil

MEA

South Africa

Browse Press Release of this Report: www.grandviewresearch.com/press-release/global-osteoporosis-drugs-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

[pharmaceuticalsindustrynews]

Boom Expected in Osteoporosis Drugs Market in Future

Human skeleton has changed drastically during the thousands of years of evolution. According to the research pubished in the PNAS (Proceedings of the National Academy of Sciences of the United States of America), a multidisciplinary science journal, the advent of agriculture and the subsequent change of human lifestyles from hunter-gatherers to farming-based have caused a considerable reduction in the weight of the human skeleton. Moreover, this has caused a sharp reduction in the bone densities of humans.

According to the World Health Organization (WHO), over 50% of the population in the world currently live in urban areas and this share is predicted to rise to 70% by 2050. This rapid urbanization is giving rise to sedentary lifestyles and unhealthy eating habits, which are, in turn, fueling the rise in the prevalence of osteoporosis across the world. Osteoporosis is a bone condition that occurs when the human body makes too little bone or loses too much bone.

Globally, the North American osteoporosis drugs market is currently very prosperous and is predicted to exhibit lucrative growth in the future years. According to industry experts, the sales of osteoporosis drugs will rise tremendously in the Asia-Pacific (APAC) region in the forthcoming years, on account of the presence of a soaring geriatric population suffering from osteoporosis and the rising adoption of unhealthy lifestyles, which negatively impact the bone health of people.

Hence, it can be said with surety that due to the ballooning incidence of osteoporosis, on account of the growing adoption of unhealthy lifestyles and consumption of fast foods, the sales of osteoporosis drugs will climb all over the world in the upcoming years.

[medicaldevicesindustrynews]

Osteoporosis Drugs Market Trends, Drivers, Growth Opportunities, Challenges, Investment Opportunities, and Recommendations

The global osteoporosis drugs market was valued at $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various classes of osteoporosis drugs, the rank ligand inhibitor segment is expected to witness the fastest growth, a CAGR of 4.3% during the forecast period. 

Osteoporosis disease is the most common bone disease, which occurs due to reduced bone mineral density and causes increased risk of fractures and fragile bones. It leads to abnormally porous bones such as sponge, which facilitate the weakening of bones and painful fracture. Most of the spine, hip, shoulder and forearm fractures occur within aged people of 65 years and above.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/osteoporosis-drugs-market/report-sample

Some of the signs and symptoms of the osteoporosis are falling risk and fractures. Diagnostic tests of osteoporosis include X-Ray test and traditional radiography tests, which is further confirmed by bone density test. Osteoporosis disease can be managed by nutrition emphasis, lifestyle management and medicines. The factors such as strict regulatory requirement for the approval of osteoporosis drugs, patent expiry of blockbuster drugs, and side-effects and complications associated with osteoporosis drugs are inhibiting the growth of the global market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=osteoporosis-drugs-market

Geographically, North America dominated the global market of osteoporosis drugs in 2015; whereas the Asia-Pacific market is expected to witness the fastest growth, a CAGR of 4.2% during the forecast period. This is due to the growing geriatric population, increasing awareness of osteoporosis drugs and increasing healthcare expenditure in the region.

Some of the key companies operating in the global osteoporosis drugs market include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Novartis International AG, Merck & Co. Inc. and Amgen Inc.

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

[pratimajadhav-blog]

Global Osteoporosis Drugs Market Research Report 2018

In this report, the global Osteoporosis Drugs market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Osteoporosis Drugs in these regions, from 2013 to 2025 (forecast), covering North America Europe China Japan Southeast Asia India

Get the sample report @ http://ytresearchgroup.com/product/global-osteoporosis-drugs-market-research-report-2018/

Global Osteoporosis Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including Eli Lilly Novartis Pfizer Amgen Merck Novo Nordisk Actavis Roche Upsher-Smith Sebela Pharma On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Bone Absorption-Inhibitor Drugs Bone Formation-Acceleration Drugs On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Male Female

If you have any special requirements, please let us know and we will offer you the report as you want.